16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii.

      Research in Microbiology
      Acinetobacter Infections, microbiology, Acinetobacter baumannii, physiology, virology, Humans, Molecular Sequence Data, Podoviridae, classification, genetics, isolation & purification, ultrastructure

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Multidrug-resistant strains of Acinetobacter baumannii (MDRAB) are increasingly being reported worldwide. Bacteriophage therapy is a potential alternative treatment for MDR bacterial infections. Although A. baumannii infection has been experimentally treated with phages, no MDRAB-specific phage has been characterized. In this study, 10 phages with differing host ranges and lysis efficacy for MDRAB were isolated; one of these, phi AB2, was further studied. Electron microscopy revealed phi AB2 to have an isometric head (60 nm), a short tail (diameter, 9 nm; length, 11 nm) and a double-stranded DNA genome--which was resistant to digestion with several restriction endonucleases--estimated to be 40 kb by pulsed-field gel electrophoresis. Partial genome sequencing of a 2.1 kb region gave sequences resembling the tubular proteins A and B of Pseudomonas aeruginosa phage LKA1. These data suggest that phi AB2 resembles phi KMV-like phages and is a new member of the Podoviridae family. It exhibited rapid adsorption (>99% adsorbed in 8 min), a short latent period (<10 min) and a large burst size (ca. 200); moreover, it was capable of infecting a wide spectrum of A. baumannii strains, causing virtually complete lysis, indicating that phi AB2 may be a good candidate as a therapeutic/disinfectant agent to control nosocomial infections caused by MDRAB. (c) 2010 Elsevier Masson SAS. All rights reserved.

          Related collections

          Author and article information

          Comments

          Comment on this article